Valneva SE (EPA:VLA)
France · Delayed Price · Currency is EUR 4.750
+0.162 (3.53%)
At close: Feb 20, 2026
Valneva SE Market Cap
Valneva SE has a market cap or net worth of €825.33 million as of February 20, 2026. Its market cap has increased by 31.05% in one year.
Market Cap
825.33M
Enterprise Value
877.71M
Revenue
179.91M
Ranking
n/a
PE Ratio
n/a
Stock Price
€4.75
Market Cap Chart
Since June 29, 2007, Valneva SE's market cap has increased from 99.08M to 825.33M, an increase of 733.01%. That is a compound annual growth rate of 12.03%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 20, 2026 | 825.33M | 28.49% |
| Dec 31, 2025 | 642.32M | 82.94% |
| Dec 31, 2024 | 351.10M | -46.40% |
| Dec 29, 2023 | 655.08M | -23.93% |
| Dec 30, 2022 | 861.12M | -66.55% |
| Dec 31, 2021 | 2.57B | 265.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Nanobiotix | 1.08B |
| Inventiva | 1.07B |
| DBV Technologies | 1.05B |
| MedinCell | 793.15M |
| Genfit | 405.33M |
| Cellectis | 252.42M |
| Transgene | 221.80M |
| MaaT Pharma | 143.76M |